Aldosterone potassium secretion

Hypoaldosteronism is defined as a deficiency of aldosterone. Renal secretion of potassium is decreased, causing hyperkalaemia. The treatment is replacement of a mineralocorticoid, e.g. fludrocortisone. 

The kidney contains the major site of renin synthesis, the juxtaglomerular cells in the wall of the afferent arteriole. From these cells, renin is secreted not only into the circulation but also into the renal interstitium. Moreover, the enzyme is produced albeit in low amounts by proximal tubular cells. These cells also synthesize angiotensinogen and ACE. The RAS proteins interact in the renal interstitium and in the proximal tubular lumen to synthesize angiotensin II. In the proximal tubule, angiotensin II activates the sodium/hydrogen exchanger (NHE) that increases sodium reabsorption. Aldosterone elicits the same effect in the distal tubule by activating epithelial sodium channels (ENaC) and the sodium-potassium-ATPase. Thereby, it also induces water reabsotption and potassium secretion. 

The major mineralocorticoid, aldosterone, is secreted by cells of the zona glomerulosa. Primary hyperaldosteronism (Conn s syndrome) is associated with potassium depletion which is, in mm, responsible for the observed neuromuscular abnormalities seen in the disorder. These are similar to those seen in hypokalemic periodic paralysis (PP), with episodic and severe exacerbations of fixed muscle weakness. Muscle biopsy shows occasional muscle necrosis and vacuoles often these feamres are accompanied by mbular aggregates as in hypokalemic PP. All these changes can be attributed to the hypokalemia and not to excess aldosterone production per se. 

As nephron mass decreases, both the distal tubular secretion and GI excretion are increased because of aldosterone stimulation. Functioning nephrons increase FEK up to 100% and GI excretion increases as much as 30% to 70% in CKD,30 as a result of aldosterone secretion in response to increased potassium levels.30 This maintains serum potassium concentrations within the normal range through stages 1 to 4 CKD. Hyperkalemia begins to develop when GFR falls below 20% of normal, when nephron mass and renal potassium secretion is so low that the capacity of the GI tract to excrete potassium has been exceeded.30... 

Potassium secretion is enhanced by aldosterone. As the concentration of K+ ions in the extracellular fluid increases, the secretion of aldosterone from the adrenal cortex also increases. The mechanism of action of aldosterone involves an increase in the activity of the Na+, K+ pump in the basolateral membrane. Furthermore, aldosterone enhances formation of K+ channels in the luminal membrane. 

Adrenocorticoid hormones are produced in the adrenal glands. They regulate a variety of metaholic processes. The most important mineralo-corticoid is aldosterone, an aldehyde as well as a ketone, which regulates the reahsorption of sodium and chloride ions in the kidney, and increases the loss of potassium ions. Aldosterone is secreted when hlood sodium ion levels are too low to cause the kidney to retain sodium ions. If sodium levels are elevated, aldosterone is not secreted, so some sodium will he lost in the urine and water. Aldosterone also controls swelling in the tissues. 

The kidney is the primary route of potassium elimination. Potassium is freely filtered with almost all of it being reabsorbed passively in the proximal tubule and the thick ascending limb of the loop of Henle. Therefore urinary potassium excretion is primarily determined by potassium secretion from the luminal cells of the distal tubule and collecting duct. The normal daily amount of potassium excreted in the urine is generally 40 to 90 mEq/L, but it can vary based on dietary intake, serum potassium concentration, and aldosterone activity. 

Aldosterone is a mineralocorticoid that is secreted from the adrenal glands in response to high serum potassium concentrations. Aldosterone promotes potassium excretion through the kidneys. Aldosterone works at the distal tubule and collecting duct to promote the reabsorption of sodium and water in exchange for potassium. The net result is potassium secretion into the urine. Aldosterone may also have extrarenal activity by stimulating cellular Na -K -ATPase pump activity. ... 

Tubular Unresponsiveness to Aldosterone Certain medical conditions, such as sickle cell anemia, systemic lupus erythematosus, and amyloidosis, can produce a defect in tubular potassium secretion, possibly as the result of an alteration in the aldosterone-binding site. The exact mechanism of the tubular unresponsiveness is unknown. 

Posttraumatic secretion of aldosterone has also been measured. Increased quantities were found to be present during surgery, and in the urine subsequently (D3, HI 7, Zl). Also, the aldosterone antagonist spironolactone will abolish postoperative sodium retention without affecting potassium secretion, illustrating the dependence of sodium displacements after surgery on the hormone (J2, M8). 

The most predominant primary effects of mineralocorticoids are adequately observed upon the cortical collecting tubule cells strategically positioned in the kidneys to enhance substantially sodium reabsorption vis-a-vis potassium secretion. This eventually leads to an elevated aldosterone titer values that actually governs, controls, and monitors effectively sodium retention and potassium depletion thereby giving rise to volume expansion and weight gain, metabolic alkalosis, and hypertension. 

Potassium secretion in the distal nephron is influenced by a variety of factors which are modulated by PG, including urinary flow rate, distal delivery of filtrate and aldosterone. Since PG tend to enhance distal delivery of filtrate and stimulate renin release, treatment with NSAID can cause hyperkalaemia. Administration of NSAID to people with normaP and impaired renal function results in positive potassium balance. In the setting of renal failure, NSAID cause a syndrome virtually indistinguishable from hyporeninaemic hypoaldosteronism (also known as Type IV renal tubular acidosis). NSAID, therefore, should not be used concurrently with other pharmacological agents that lead to positive potassium balance. 

A hormone produced in the adrenal gland, aldosterone, signals the kidneys to excrete or retain potassium based on the body s needs. If potassium levels are high, aldosterone is secreted, causing an increase in potassium excretion into the urine. Serum levels of potassium also are influenced by the levels of other electrolytes and acid-base balance. In alkalosis, for example, potassium may shift out of the cell as hydrogen ions shift into the cell to buffer the excessive acid, and when serum potassium concentration is low, potassium is retained by excreting sodium and chloride. 

No specific hormone is known to regulate potassium excretion, but aldosterone indirectly influences potassium excretion by facilitating sodium reabsorption. Nevertheless, potassium secretion is not necessarily altered by the aldosterone response to sodium metabolism, and low sodium levels are not necessarily asso-... 

Spironolactone is the most clinically usehil steroidal aldosterone antagonist, and unlike GR antagonists, this compound is utilized much more frequendy than aldosterone agonists. Interfering with reabsorption and secretion in the late distal segment, this compound is predominantiy used with other diuretics. Canrenone, an olefinic metaboHte of spironolactone, and potassium canrenoate, in which the C-17 lactone has been hydrolyzed open, are also potent mineralocorticoid antagonists. 

In an attempt to conserve sodium, the kidney secretes renin increased plasma renin activity increases the release of aldosterone, which regulates the absorption of potassium and leads to kafluresis and hypokalemia. Hypokalemia is responsible in part for decreased glucose intolerance (82). Hyponatremia, postural hypotension, and pre-renal azotemia are considered of tittle consequence. Hypemricemia and hypercalcemia are not unusual, but are not considered harmful. However, hypokalemia, progressive decreased glucose tolerance, and increased semm cholesterol [57-88-5] levels are considered... 

Hyperaldosteronism is a syndrome caused by excessive secretion of aldosterone. It is characterized by renal loss of potassium. Sodium reabsorption in the kidney is increased and accompanied by an increase in extracellular fluid. Clinically, an increased blood pressure (hypertension) is observed. Primary hyperaldosteronism is caused by aldosterone-producing, benign adrenal tumors (Conn s syndrome). Secondary hyperaldosteronism is caused by activation of the renin-angiotensin-aldosterone system. Various dtugs, in particular diuretics, cause or exaggerate secondary peadosteronism. 

Aldosterone A hormone produced in and secreted by the zona glomerulosa of the adrenal cortex. Aldosterone acts on the kidneys to reabsorb sodium and excrete potassium. It is also a part of the renin-angiotensin-aldosterone system, which regulates blood pressure and blood volume. 

The mechanism by which potassium regulates aldosterone secretion is unclear however, this ion appears to have a direct effect on the adrenal cortex. An increase in the level of potassium in the blood stimulates the release of aldosterone. The effect of aldosterone on the kidney then decreases the level of potassium back to normal. 

Triamterene is a pyrazine derivative that inhibits reabsorption of sodium ions without increasing excretion of potassium ions. It exhibits the same approximate effect as spironolactone however, it does not competitively bind with aldosterone receptors. Its action does not have an effect on secretion of aldosterone or its antagonists, which are a result of direct action on renal tubules. 

Aldosterone stimulates the rates of Na+ reabsorption and K+ secretion. This is relevant to the action of spironolactone, a diuretic that is a competitive inhibitor of aldosterone (discussed later). It is also pertinent because administration of diuretics can cause secondary hyperaldosteronism, which may exaggerate the potassium wasting that is a consequence of the increased delivery of Na+ and enhanced flow through distal convoluted tubules and collecting ducts. 

Potassium-sparing diuretics prevent K+ secretion by antagonizing the effects of aldosterone at the late distal and cortical collecting tubules. Inhibition may occur by direct pharmacologic antagonism of mineralocorticoid receptors ( spironolactone, eplerenone ) or... 

Spironolactone and eplerenone bind to mineralocorticoid receptors and blunt aldosterone activity. Amiloride and triamterene do not block aldosterone, but instead directly interfere with Na+ entry through the epithelial Na+ channels (ENaC) in the apical membrane of the collecting tubule. Since K+ secretion is coupled with Na+ entry in this segment, these agents are also effective potassium-sparing diuretics. 

---